1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2 |
XIA C F, DONG X S, LI H, et al. Cancer Statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
|
3 |
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program[DB/OL]. (2022-04)[2022-10-28]. https://seer.cancer.gov/statistics-network/explorer.
|
4 |
PIGNON J P, TRIBODET H, SCAGLIOTTI G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group[J]. J Clin Oncol, 2008, 26(21): 3552-3559.
|
5 |
MELOSKY B, KAMBARTEL K, HÄNTSCHEL M, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis[J]. Mol Diagn Ther, 2022, 26(1): 7-18.
|
6 |
KHOO C, ROGERS T M, FELLOWES A, et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond[J]. Transl Lung Cancer Res, 2015, 4(2): 126-141.
|
7 |
HERBST R S. Review of epidermal growth factor receptor biology[J]. Int J Radiat Oncol Biol Phys, 2004, 59(2 Suppl): 21-26.
|
8 |
REITA D, PABST L, PENCREACH E, et al. Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring[J]. Cancers, 2021, 13(19): 4926.
|
9 |
ELLISON G, ZHU G S, MOULIS A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples[J]. J Clin Pathol, 2013, 66(2): 79-89.
|
10 |
DALURZO M L, AVILÉS-SALAS A, SOARES F A, et al. Testing for EGFR mutations and ALK rearrangements in advanced non-small-cell lung cancer: considerations for countries in emerging markets[J]. Onco Targets Ther, 2021, 14: 4671-4692.
|
11 |
LINDEMAN N I, CAGLE P T, AISNER D L, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology[J]. J Mol Diagn, 2018, 20(2): 129-159.
|
12 |
GOLDMAN J W, NOOR Z S, REMON J, et al. Are liquid biopsies a surrogate for tissue EGFR testing? [J]. Ann Oncol, 2018, 29(suppl_1): i38-i46.
|
13 |
RECK M, HAGIWARA K, HAN B H, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study[J]. J Thorac Oncol, 2016, 11(10): 1682-1689.
|
14 |
HAN B H, TJULANDIN S, HAGIWARA K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study[J]. Lung Cancer, 2017, 113: 37-44.
|
15 |
KRUG A K, ENDERLE D, KARLOVICH C, et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma[J]. Ann Oncol, 2018, 29(3): 700-706.
|
16 |
PASCUAL J, ATTARD G, BIDARD F C, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group[J]. Ann Oncol, 2022, 33(8): 750-768.
|
17 |
TSUBOI M, KATO H, NAGAI K J, et al. Gefitinib in the adjuvant setting: safety results from a phase Ⅲ study in patients with completely resected non-small cell lung cancer[J]. Anticancer Drugs, 2005, 16(10): 1123-1128.
|
18 |
ZHONG W Z, WANG Q, MAO W M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ‒ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19(1): 139-148.
|
19 |
ZHONG W Z, WANG Q, MAO W M, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ‒ⅢA (N1‒N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase Ⅲ trial[J]. J Clin Oncol, 2021, 39(7): 713-722.
|
20 |
TADA H, MITSUDOMI T, MISUMI T, et al. Randomized phase Ⅲ study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage Ⅱ ‒ⅢA non-small-cell lung cancer with EGFR mutation (IMPACT)[J]. J Clin Oncol, 2022, 40(3): 231-241.
|
21 |
HE J X, SU C X, LIANG W H, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ‒ⅢA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9): 1021-1029.
|
22 |
WU Y L, TSUBOI M, HE J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
|
23 |
KELLY K, ALTORKI N K, EBERHARDT W E E, et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB‒ⅢA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(34): 4007-4014.
|
24 |
YUE D S, XU S D, WANG Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respir Med, 2018, 6(11): 863-873.
|
25 |
PENNELL N A, NEAL J W, CHAFT J E, et al. SELECT: a phase Ⅱ trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer[J]. J Clin Oncol, 2019, 37(2): 97-104.
|
26 |
LIU Y T, HAO X Z, LIU D R, et al. Icotinib as adjuvant treatment for stage Ⅱ‒ⅢA lung adenocarcinoma patients with EGFR mutation (ICWIP study): study protocol for a randomised controlled trial[J]. Cancer Manag Res, 2020, 12: 4633-4643.
|
27 |
WANG S Y. Icotinib following chemotherapy versus chemotherapy as adjuvant therapy in stage ⅡA‒ⅢA NSCLC with EGFR mutation (ICTAN)[EB/OL]. (2018-08-28)[2022-06-29]. https://www.clinicaltrials.gov/ct2/show/NCT01996098.
|
28 |
WANG S Y. Icotinib for completed resected ⅠB NSCLC with EGFR mutation (CORIN)[EB/OL]. (2021-08-03)[2022-06-29]. https://clinicaltrials.gov/ct2/show/NCT02264210.
|
29 |
HSU W H, YANG J C H, MOK T S, et al. Overview of current systemic management of EGFR-mutant NSCLC[J]. Ann Oncol, 2018, 29(suppl_1): i3-i9.
|
30 |
NEAL J W, COSTA D B, MUZIKANSKY A, et al. Randomized phase Ⅱ study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage Ⅰ‒Ⅲ EGFR-mutant non-small-cell lung cancer[J]. JCO Precis Oncol, 2021, 5: 325-332.
|
31 |
KOCH A L, VELLANKI P J, DREZNER N, et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative project orbis review[J]. Clin Cancer Res, 2021, 27(24): 6638-6643.
|
32 |
BRADBURY P, SIVAJOHANATHAN D, CHAN A, et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review[J]. Clin Lung Cancer, 2017, 18(3): 259-273.e8.
|
33 |
PISTERS K, KRIS M G, GASPAR L E, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ‒ⅢA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update[J]. J Clin Oncol, 2022, 40(10): 1127-1129.
|
34 |
CHEEMA P K, HEEG B, DYER M, et al. 1165P Modelling long-term survival outcomes in patients with stage (stg) ⅠB‒ⅢA EGFR-mutated NSCLC from the ADAURA trial[J]. Ann Oncol, 2021, 32: S936-S937.
|
35 |
PASSARO A, LEIGHL N, BLACKHALL F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(5): 466-487.
|
36 |
LEONETTI A, SHARMA S, MINARI R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737.
|
37 |
DI NOIA V, D'AVENI A, D'ARGENTO E, et al. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies[J]. ESMO Open, 2021, 6(6): 100280.
|
38 |
JÄNNE P A, BAIK C, SU W C, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer[J]. Cancer Discov, 2022, 12(1): 74-89.
|
39 |
SHU C A, GOTO K, OHE Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2[J]. J Clin Oncol, 2022, 40(16_suppl): 9006.
|
40 |
GAO S G. Efficacy and safety of almonertinib combined with or without chemotherapy as an adjuvant treatment for stage Ⅱ‒ⅢA non-small cell lung carcinoma following complete tumour resection (APEX)[EB/OL]. (2022-02-24)[2022-06-30]. https://clinicaltrials.gov/ct2/show/NCT04762459.
|
41 |
HE J X, LIANG W H. To assess the efficacy and safety of furmonertinib versus placebo, in patients with epidermal growth factor receptor mutation positive stage Ⅱ‒ⅢA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy (FORWARD) [EB/OL]. (2021-04-21)[2022-06-30]. https://clinicaltrials.gov/ct2/show/NCT04853342.
|
42 |
RECK M, REMON J, HELLMANN M D. First-line immunotherapy for non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6): 586-597.
|
43 |
FELIP E, ALTORKI N, ZHOU C C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB‒ⅢA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308): 1344-1357.
|